Review on Current Good Manufacturing Practices
Anushka Sathe1, Shinde Ganesh S1*, Jadhav Ravindra S2, Khule Shubham1, Madhvi Joshi1,
Bhawar Kartik1, Gade Supriya1, Kharat prapti1, Bhoir Bhumika1, Diksha Bhande1
1Department of Pharmaceutics, Institute of Pharmacy, Loni.
2Department of Phgarmacognosy, Institute of Pharmacy, Loni.
*Corresponding Author E-mail:
Abstract:
Current Good Manufacturing Practices (cGMP) form the backbone of quality assurance in the pharmaceutical industry, ensuring that medicinal products are consistently manufactured and controlled to meet established standards of safety, efficacy, and quality. cGMP encompasses a comprehensive set of regulatory principles covering all stages of pharmaceutical production, including facility design, equipment qualification, material control, validated manufacturing processes, documentation systems, and quality management practices. Regulatory authorities such as the USFDA, WHO, EMA, and CDSCO enforce cGMP requirements to minimize risks that cannot be detected through final product testing alone, including contamination, mix-ups, deviations, and data integrity failures. Over time, cGMP has evolved from a prescriptive compliance model to a science- and risk-based quality system integrating modern concepts such as Quality by Design, Quality Risk Management, Process Analytical Technology, and continuous improvement. Global harmonization of GMP standards through WHO, ICH, PIC/S, and national regulations has facilitated international regulatory convergence and strengthened oversight of global supply chains. This review outlines the fundamental principles, regulatory frameworks, and key components of GMP, with emphasis on quality management, validation, documentation, personnel, premises, and inspection systems. Understanding and effective implementation of cGMP are essential for maintaining regulatory compliance, ensuring consistent product quality, and protecting patient health.
KEYWORDS: Good Manufacturing Practices (GMP), Healthcare industry, Quality control, Product safety, Regulatory compliance.
Current Good Manufacturing Practices (cGMP) constitute a comprehensive system of regulations, guidelines, and quality principles designed to ensure that pharmaceutical products are consistently manufactured and controlled to meet required quality standards. The term “current” highlights the necessity for pharmaceutical manufacturers to employ up-to-date technologies, scientific knowledge, and management practices in drug production. Regulatory authorities such as the United States Food and Drug Administration (USFDA), World Health Organization (WHO), European Medicines Agency (EMA), and India’s Central Drugs Standard Control Organization (CDSCO) enforce cGMP requirements to safeguard public health and ensure the safety, efficacy, and quality of medicinal products.1
The core objective of cGMP is to reduce risks inherent in pharmaceutical manufacturing processes that cannot be adequately controlled through final product testing alone. These risks include microbial contamination, cross-contamination, mix-ups, deviations, and documentation errors. cGMP guidelines encompass all aspects of manufacturing operations, including infrastructure and facility design, equipment qualification and maintenance, control of raw materials and packaging materials, validated manufacturing processes, proper documentation practices, and robust quality assurance and quality control systems. Equally important is the role of trained and competent personnel, as human error remains a significant source of quality failures in pharmaceutical production.
Over time, cGMP has evolved from a rule-based compliance framework to a more scientific and risk-based quality management system. Contemporary cGMP implementation increasingly integrates concepts such as Quality by Design (QbD), Quality Risk Management (QRM), Process Analytical Technology (PAT), and continuous improvement. These approaches enhance process understanding, enable proactive identification and mitigation of risks, and support consistent product quality throughout the product lifecycle. Additionally, data integrity, electronic documentation, and computerized systems validation have emerged as critical components of modern cGMP compliance.2
With the globalization of pharmaceutical manufacturing and supply chains, harmonization of cGMP standards has become essential. International regulatory expectations, including ICH guidelines and WHO GMP standards, facilitate mutual recognition and regulatory convergence across countries. Non-compliance with cGMP can lead to serious consequences such as regulatory warning letters, product recalls, import bans, and risks to patient safety. Therefore, effective implementation and continual updating of cGMP systems are crucial for pharmaceutical manufacturers to maintain regulatory compliance, ensure product quality, and uphold public trust.This review aims to discuss the principles, regulatory perspectives, recent developments, and implementation challenges associated with current Good Manufacturing Practices in the pharmaceutical industry.3
GMP is a system that ensures products are consistently produced and controlled according to established quality standards, minimizing risks such as contamination, errors, and variations in production.
1. Quality Built into the Product:
Quality should be ensured at every stage of manufacturing, from raw material procurement to final product release, rather than relying solely on end-product testing.
2. Clear, Written, and Approved Procedures:
All manufacturing and quality control activities must be governed by clearly written, reviewed, and approved Standard Operating Procedures (SOPs) to ensure consistency and reproducibility.
3. Validation of Processes and Methods:
Critical processes, analytical methods, and cleaning procedures must be validated to demonstrate that they consistently produce products meeting predefined quality specifications.
4. Accurate Documentation and Record-Keeping:
Proper documentation ensures traceability, accountability, and transparency, facilitating investigations, audits, and regulatory compliance.
5. Clean and Hygienic Manufacturing Environment:
Facilities must be designed, maintained, and operated to prevent contamination through effective sanitation, environmental monitoring, and hygienic practices.
6. Prevention of Contamination and Mix-Ups:
Adequate controls such as proper labeling, segregation of materials, controlled workflows, and validated cleaning procedures must be implemented to avoid cross-contamination and product mix-ups.
7. Trained and Qualified Personnel:
Personnel involved in manufacturing and quality assurance must be appropriately trained, competent, and aware of their GMP responsibilities.
8. Properly Maintained and Calibrated Equipment:
Equipment must be suitably designed, regularly maintained, cleaned, and calibrated to ensure accurate and reliable operation.
9. Evaluation and Control of Changes
Any changes in materials, processes, equipment, or systems must be systematically evaluated, approved, documented, and implemented through an effective change control system.
10. Regular Self-Inspection and Audits:
Periodic self-inspections and internal audits help assess GMP compliance, identify deficiencies, and promote continuous improvement.4
GOOD MANUFACTURING PRACTICES (GMP) GUIDELINES:
Good Manufacturing Practices (GMP) guidelines are regulatory frameworks established to ensure that pharmaceutical products, medical devices, and active pharmaceutical ingredients (APIs) are consistently manufactured and controlled according to quality standards appropriate for their intended use. Many countries have enacted legislation requiring pharmaceutical and medical device manufacturers to develop and comply with GMP guidelines that align with national regulatory requirements. The fundamental objective of GMP is to safeguard patient health while ensuring the production of safe, effective, and high-quality medicinal products.
The formalization of GMP began in the early 1960s, following increased awareness of drug safety and quality failures. Since then, GMP guidelines have been adopted and enforced in over 100 countries worldwide, ranging from developing nations to highly industrialized regions. Although specific requirements may vary among regulatory authorities, the core principles of GMP remain globally harmonized, allowing some flexibility in interpretation while maintaining consistent product quality.5
Major International GMP Guidelines:
1. Pharmaceutical Inspection Convention / Pharmaceutical Inspection Co-operation Scheme (PIC/S):
PIC/S provides a comprehensive Guide to GMP for pharmaceutical products and facilitates cooperation between regulatory authorities. Member countries include Australia, Austria, Belgium, Canada, Denmark, Finland, France, Hungary, Ireland, Italy, Latvia, Liechtenstein, Malaysia, the Netherlands, Norway, Poland, Portugal, Romania, Singapore, the Slovak Republic, Spain, Sweden, Switzerland, and the United Kingdom.
2. Association of South-East Asian Nations (ASEAN) GMP:
ASEAN GMP provides general guidelines aimed at harmonizing pharmaceutical manufacturing standards within Southeast Asia. Participating countries include Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
3. European Union / European Economic Community (EU-GMP):
The EU-GMP guidelines apply to medicinal products manufactured or marketed within the European Union. These guidelines are enforced across member states such as Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden, and the United Kingdom, ensuring a uniform regulatory framework.
4. United States cGMP (USFDA):
In the United States, GMP is enforced by the Food and Drug Administration (FDA) under Section 501(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 351). The term “current Good Manufacturing Practices (cGMP)” emphasizes the requirement for manufacturers to apply up-to-date technologies and systems in compliance with evolving regulatory expectations.
5. World Health Organization (WHO) GMP:
WHO GMP is widely adopted by regulatory authorities and pharmaceutical industries in over 100 countries, particularly in developing regions. It serves as a benchmark for ensuring quality, safety, and efficacy of medicines in countries such as Nepal and other low- and middle-income nations.
6. National GMP Frameworks:
Several countries have established advanced national GMP systems aligned with international standards, including Australia (Therapeutic Goods Administration – TGA), Japan, Canada, and Singapore. In the United Kingdom, GMP requirements are governed under the Medicines Act, 1968, commonly referred to as the “Orange Guide”.6
Regulatory Authorities Conducting GMP Inspections:
1. United Kingdom – Medicines and Healthcare Products Regulatory Agency (MHRA)
2. United States – Food and Drug Administration (FDA)
3. European Union – National competent authorities under EU-GMP
4. Australia – Therapeutic Goods Administration (TGA)
5. South Africa – Medicines Control Council (MCC)
6. Brazil – ANVISA (Agência Nacional de Vigilância Sanitária)
7. India – State Food and Drug Administration (FDA) reporting to CDSCO
8. Nepal – Department of Drug Administration (DDA)
9. Pakistan – Ministry of Health
10. Nigeria – National Agency for Food and Drug Administration and Control (NAFDAC)7
Good Manufacturing Practices (GMP) require that the entire manufacturing process is clearly defined, validated, and controlled before commercial production is initiated. All necessary facilities, utilities, and systems must be in place to ensure consistent product quality. In practical terms, GMP demands that personnel are adequately trained, suitable premises and equipment are used, approved materials are handled correctly, validated procedures are followed, appropriate storage and transportation conditions are maintained, and accurate records are generated and retained. These requirements collectively ensure that pharmaceutical products are consistently manufactured in compliance with predefined quality standards.
The essential components of GMP encompass personnel, premises, equipment, documentation, production controls, quality control, sanitation, validation, storage, distribution, and self-inspection. Together, these components form an integrated system designed to prevent errors, contamination, mix-ups, and deviations during manufacturing operations.
Figure 1: Components of GMP
In India, Good Manufacturing Practice (GMP) requirements for pharmaceutical products are governed by Schedule M of the Drugs and Cosmetics Rules, which lays down standards for premises, plant, and equipment. Schedule M is structured into different parts based on product categories and manufacturing operations.
Part I specifies the general GMP requirements applicable to all pharmaceutical manufacturers. These include provisions related to warehousing, production and quality control areas, personnel qualifications, sanitation and hygiene, manufacturing operations, handling of raw materials, equipment, documentation and records, labeling, quality assurance, self-inspection, validation, product recalls, complaint handling, adverse drug reaction monitoring, and maintenance of a site master file.
Parts IA to IE describe specific GMP requirements for different pharmaceutical product categories, while Part IF outlines requirements for premises, plant, and materials for the manufacture of active pharmaceutical ingredients (bulk drugs). Part II provides detailed requirements for plant and equipment for various dosage forms improvement.8
The holder of a manufacturing authorization is responsible for ensuring that medicinal products are consistently manufactured to be fit for their intended use, comply with marketing authorization requirements, and do not pose any risk to patients due to inadequate safety, quality, or efficacy. Achievement of these quality objectives is the responsibility of senior management and requires active participation and commitment from personnel across all departments and organizational levels, including suppliers and distributors. In the pharmaceutical industry, quality management is defined as the management function that establishes and implements the organization’s quality policy, reflecting its overall intention and direction regarding quality, as formally authorized by top management.9
Quality Assurance (QA) is a comprehensive concept encompassing all activities that individually or collectively influence the quality of a pharmaceutical product. It represents the totality of organized arrangements designed to ensure that products consistently meet the quality standards required for their intended use. QA incorporates Good Manufacturing Practices (GMP) along with additional elements such as product design and development.10
An effective QA system should ensure that:
1. Pharmaceutical products are designed and developed in compliance with GMP, GLP, and GCP requirements.
2. Production and control operations are clearly defined in written procedures and consistently followed.
3. Appropriate arrangements exist for the procurement, handling, and use of correct starting and packaging materials.
4. Necessary controls, including in-process testing, calibrations, and validations, are carried out.
5. Finished products are released only after certification by authorized personnel confirming compliance with marketing authorization and regulatory requirements.
6. Adequate storage, distribution, and handling systems are maintained throughout the product shelf life.
7. Deviations are reported, investigated, and documented.
8. Regular product quality reviews are conducted to ensure process consistency and continuous improvement.11
GMP is an integral part of QA and ensures that pharmaceutical products are consistently produced and controlled according to quality standards appropriate for their intended use and marketing authorization. GMP primarily aims to minimize risks inherent in pharmaceutical manufacturing.12
The basic requirements of GMP include:
1. Clearly defined and systematically reviewed manufacturing processes capable of consistently producing quality products.
2. Qualification and validation of facilities, equipment, and processes.
3. Availability of adequate resources, including trained personnel and suitable premises.
4. Clear, unambiguous written instructions and procedures.
5. Proper training of operators to perform procedures correctly.
6. Accurate and contemporaneous manufacturing records, with deviations recorded and investigated.
7. Retention of manufacturing and distribution records enabling full batch traceability.
8. Proper storage and distribution systems to protect product quality.
9. An effective product recall system.
10. Investigation of complaints and implementation of corrective and preventive actions.13
Quality Control is a component of GMP concerned with sampling, testing, specifications, documentation, and release procedures. QC ensures that materials and products are not released for use or sale until their quality has been verified as satisfactory. QC activities include establishing and validating test methods, maintaining reference standards, monitoring product stability, ensuring correct labeling, participating in complaint investigations, and conducting environmental monitoring.14
A high level of sanitation and hygiene must be maintained in all aspects of pharmaceutical manufacturing. This includes personnel, premises, equipment, materials, containers, and cleaning agents. An integrated sanitation and hygiene program should eliminate potential sources of contamination. Effective cleaning must precede disinfection, as dirt and organic matter can inactivate disinfectants and protect microorganisms.15
Qualification ensures that premises, utilities, and equipment operate correctly, while validation provides documented evidence that processes consistently produce products meeting predefined specifications. Qualification and validation include:
1. Design Qualification (DQ)
2. Installation Qualification (IQ)
3. Operational Qualification (OQ)
4. Process Validation / Performance Qualification (PV/PQ)16
Despite preventive systems, defects may occur; therefore, an effective complaint handling and recall system is essential. Complaints must be evaluated by qualified personnel using production, packaging, distribution records, and retained samples. Complaint evaluation helps assess patient risk, identify process improvements, and maintain customer confidence.
With increased outsourcing in the pharmaceutical industry, contract manufacturing and testing have gained importance. Responsibilities and quality standards must be clearly defined through written agreements to avoid misunderstandings and ensure GMP compliance.17
Self-inspection programs assess GMP compliance and identify areas for improvement. Inspections should be conducted by trained, objective personnel and may be routine or triggered by events such as recalls or regulatory inspections.
Qualified and well-trained personnel are essential for GMP compliance. Responsibilities must be clearly defined, and personnel should receive continuous training in GMP principles and hygiene. Human factors play a critical role in ensuring product quality and patient safety.
Premises must be suitably designed, constructed, and maintained to minimize errors and contamination. Walls, floors, ceilings, utilities, doors, and windows should be smooth, cleanable, and resistant to cleaning agents, ensuring ease of maintenance and hygiene.18
Equipment must be designed to produce products of consistent quality and allow thorough cleaning. Product-contact surfaces should be smooth and free from crevices. Equipment must withstand repeated cleaning, disinfection, or sterilization to prevent contamination.
1. Site Master File
2. Quality Manual
3. Policies
4. SOPs
5. Batch Processing and Packaging Records
6. Test Methods
7. Logbooks
CONCLUSION:
Good Manufacturing Practices are essential for ensuring the consistent quality, safety, and efficacy of pharmaceutical products throughout their lifecycle. GMP provides a structured framework that integrates quality management, validated processes, competent personnel, appropriate facilities, and robust documentation systems to prevent errors and minimize manufacturing risks. The evolution of GMP toward risk-based and science-driven approaches has strengthened pharmaceutical quality systems and enabled proactive control of critical processes. Harmonization of GMP standards at national and international levels has further enhanced regulatory consistency and global market access. However, effective GMP implementation requires continuous commitment from senior management, regular training of personnel, and ongoing system improvements to address emerging challenges such as data integrity and complex supply chains. Sustained adherence to GMP principles not only ensures regulatory compliance but also builds public confidence in pharmaceutical products and ultimately safeguards patient health.
REFERENCES:
1. Ravishankar Ahirwar. Good Manufacturing Practices (GMP) compliance in the pharmaceutical sector. Int J Innov Eng Res & Manag. 2025; 12(2):51–55.
2. Jameela Helen Jacobs, Margret Chandira R, Deepu S, Benny KJ. A glance to the story of Good Manufacturing Practices for pharmaceuticals. J Biomed Pharm Res. 2020; 9(3). doi:10.32553/jbpr.v9i3.752
3. Pallavi Gorukanti, Satheesh Jogala, Narender Boggula, Sucharitha Makula. Good Manufacturing Practices and documentation in pharmaceutical production: a comprehensive review. Asian J Pharm Res Dev. 2025; 13(6):86–95. doi:10.22270/ajprd.v13i6.1676
4. Shinde G, Godage RK, Jadhav RS, Manoj B, Aniket B. A Review on Advances in UV Spectroscopy. Research Journal of Science and Technology. 2020; 12(1):47-51.
5. Akash Sharma, Vriti Gamta, Gaurav Luthra. The importance of Good Manufacturing Practices (GMP) in the healthcare industry. J Pharm Res Int. 2023; 35(18):75–90. doi:10.9734/jpri/2023/v35i187394
6. Shinde GS, Rao PS, Jadhav RS, Kolhe P, Athare D. A review on chromatography and advancement in paper chromatography technique. Asian Journal of Pharmaceutical Analysis. 2021; 11(1):45-8
7. Al Azawei A, Loughrey K, Surim K, Connolly ME, Naughton BD. The management of good manufacturing practice (GMP) inspections: a scoping review of the evidence. Front Med (Lausanne). 2025; 12:1687864. doi:10.3389/fmed.2025.1687864
8. Poli M, Quaglierini M, Zega A, Pardini S, Telleschi M, Iervasi G, Guiducci L. Risk management in Good Manufacturing Practice (GMP) radiopharmaceutical preparations. Appl Sci. 2024; 14(4):1584. doi:10.3390/app14041584
9. Shinde, G. S., Jadhav, R., Vikhe, D., & Kote, R. B.Development and evaluation of herbal fast disintegrating tablet of Achyranthes aspera linn root extract. Asian Journal of Pharmacy and Technology, 2024:14(2), 119-122.
10. Jurun Mclean. Good Manufacturing Practices (GMP) in pharmaceuticals: Ensuring quality and safety. Int J Pharm. 2023; 13(6):3–4. doi:10.37532/2249-1848.2023.13(6).74
11. Sanjay Kumar Jain, Rajesh Kumar Jain. Evolution of GMP in Pharmaceutical Industry. Research J. Pharm. and Tech. 2017; 10(2): 601-606. doi: 10.5958/0974-360X.2017.00118.4
12. Hemanth KG, et al. Pharmaceutical Defects: A critical review on defects of various dosage forms and regulatory impacts. Research Journal of Pharmacy and Technology. 2020 Sep; 13(9):4505–8. doi: 10.5958/0974-360X.2020.00794.5
13. Shinde, G. S, Jadhav R S, Tambe V B, Kote R B.RP-HPLC Method Development and Validation of Lamivudine, Zidovudine and Nevirapine in Bulk and Dosage form using UV Detector." Research Journal of Pharmacy and Technology 17.10 (2024): 5011-5015
14. Godge RK, Shinde GS, Joshi S. Simultaneous Estimation and Validation of Dapagliflozin and Saxagliptin in Bulk Drug and Dosage Form by RP-HPLC. Research Journal of Science and Technology. 2019; 11(1):59-63
15. Raul S, Padhy G, Mahapatra A, Charan S. An Overview of Concept of Pharmaceutical Validation. Research Journal of Pharmacy and Technology. 2014 Sep; 7(9):1081-90.
16. Shinde GS, Jadhav RS, Kote RB, Kadam AJ, Bankar AA. Bioanalytical Method Development and Validation of UV Spectrophotometric Method for Estimation of Metformin Hydrochloride in Urine Sample. Asian J Res Chem. 2024; 17(2):93–6. doi: 10.52711/0974-4150.2024.00019
17. Kulkarni S, Panda A, Tiwari R. Pharmaceutical Process Validation: A Key Requirement for Quality Attribute. Research Journal of Pharmacy and Technology. 2014; 7(1):74-7
18. Darshan A. Salade, Kishor S. Arote, P. H. Patil, Vikas V. Patil, Amol R. Pawar. A Brief Review on Pharmaceutical Validation. Asian Journal of Pharmaceutical Analysis. 2022; 12(3):211-7. doi: 10.52711/2231-5675.2022.00035.
19. Anju G, Pandey P. Process Validation of Pharmaceutical Dosages Form: A Review. Biomedical Journal of Scientific and Technical Research. 2017; 1(5):1467–75.
|
Received on 16.01.2026 Revised on 11.02.2026 Accepted on 04.03.2026 Published on 25.04.2026 Available online from April 28, 2026 Research J. Science and Tech. 2026; 18(2):232-238. DOI: 10.52711/2349-2988.2026.00032
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|